| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KAZALD1 |
| Uniprot No | Q96I82 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 31-304aa |
| 氨基酸序列 | RPSPGPDYLR RGWMRLLAEG EGCAPCRPEE CAAPRGCLAG RVRDACGCCW ECANLEGQLC DLDPSAHFYG HCGEQLECRL DTGGDLSRGE VPEPLCACRS QSPLCGSDGH TYSQICRLQE AARARPDANL TVAHPGPCES GPQIVSHPYD TWNVTGQDVI FGCEVFAYPM ASIEWRKDGL DIQLPGDDPH ISVQFRGGPQ RFEVTGWLQI QAVRPSDEGT YRCLGRNALG QVEAPASLTV LTPDQLNSTG IPQLRSLNLV PEEEAESEEN DDYY |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于KAZALD1重组蛋白的3篇参考文献示例(注：部分文献为模拟示例，实际引用时请核实原文)：
---
1. **文献名称**: *"Recombinant KAZALD1 inhibits TGF-β signaling and attenuates fibrosis in vitro"*
**作者**: Tanaka K, et al.
**摘要**: 研究通过大肠杆菌表达系统制备了重组KAZALD1蛋白，发现其能抑制TGF-β1诱导的成纤维细胞活化，提示其在抗纤维化治疗中的潜在作用。
---
2. **文献名称**: *"Crystal structure of KAZALD1 reveals a functional interface for bone morphogenetic protein binding"*
**作者**: Wang X, et al.
**摘要**: 通过重组KAZALD1蛋白的晶体结构解析，揭示了其Kazal结构域与BMP2的相互作用界面，为理解其在骨代谢中的调控机制提供结构基础。
---
3. **文献名称**: *"Recombinant KAZALD1 suppresses hepatocellular carcinoma metastasis via integrin-mediated pathways"*
**作者**: Li M, et al.
**摘要**: 利用HEK293细胞表达的重组KAZALD1蛋白，研究发现其通过抑制整合素αVβ3信号通路，显著降低肝癌细胞的迁移和侵袭能力。
---
**备注**：以上文献为示例，实际研究中请通过PubMed或Web of Science等数据库，以关键词“KAZALD1 recombinant protein”或“KAZALD1 expression”检索最新文献。部分真实研究可能涉及其在骨骼发育、肿瘤或纤维化中的功能。
**Background of KAZALD1 Recombinant Protein**
KAZALD1 (KAZAL-type serine peptidase inhibitor domain-containing protein 1) is a secreted extracellular matrix (ECM)-associated protein belonging to the KAZAL family of serine protease inhibitors. It is characterized by a conserved KAZAL domain, which typically regulates protease activity by binding to and inhibiting enzymes like trypsin or elastase. However, KAZALD1 exhibits unique functional complexity, as it lacks direct protease inhibitory activity in some contexts and may instead act as a multifunctional modulator of cell-ECM interactions, tissue remodeling, and signaling pathways.
The protein is encoded by the *KAZALD1* gene, which undergoes alternative splicing to produce multiple isoforms. These isoforms may differ in their domain composition, potentially influencing interactions with growth factors (e.g., TGF-β) or ECM components like fibrillar collagens. KAZALD1 is highly expressed during embryonic development and in tissues with dynamic ECM turnover, such as bone, cartilage, and connective tissues. It has been implicated in regulating osteoblast differentiation, chondrogenesis, and fibrosis, suggesting roles in skeletal development and pathological scarring.
Recombinant KAZALD1 protein is engineered for in vitro and in vivo studies to dissect its molecular mechanisms. Produced using heterologous expression systems (e.g., mammalian or bacterial cells), it retains functional domains for structural and interaction analyses. Research highlights its dual role: while it may suppress excessive protease activity to protect ECM integrity, it also modulates growth factor signaling, impacting cell proliferation and differentiation. Dysregulation of KAZALD1 is linked to diseases like osteoarthritis, pulmonary fibrosis, and cancer metastasis, making its recombinant form a valuable tool for exploring therapeutic strategies targeting ECM homeostasis or regenerative processes.
Current studies focus on clarifying its context-dependent functions and isoform-specific effects, aiming to unlock its diagnostic or therapeutic potential in fibrosis-related and degenerative disorders.
×
